

ASX ANNOUNCEMENT

9 February 2023

\$35 Million Capital Raising

Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) has placed 1.458 million new ordinary shares in the Company (**New Shares**) to various sophisticated and professional investors at an issue price of \$24.00 per New Share¹, raising \$35 million (**Placement**).

The company's two largest holders Perceptive Advisors and L1 Capital cornerstoned the Placement, each subscribing beyond their existing pro-rata shareholding.

Proceeds from the Placement will be used primarily for the clinical development of DurAVR™, the Company's 3D single-piece aortic valve for the treatment of aortic stenosis and for general working capital purposes.

Participants in the Placement will also receive one attaching unlisted option to acquire an ordinary share in Anteris for each New Share, expiring two years from the date of issue with an exercise price of \$29.00 (**New Options**).

Wayne Paterson, Chief Executive Officer and Managing Director, has also entered into a binding agreement to invest in the capital raise on the same terms amounting to \$100,008. This investment is subject to shareholder approval and will be considered at the Annual General Meeting.

The issue of New Shares will be made under the Company's available placement capacity under Listing Rules 7.1 and 7.1A, and the issue of the New Options and Lead Manager Options will be made under the Company's available placement under Listing Rule 7.1.

It is expected that settlement of the Placement will occur on 14 February 2023 (with issue of the New Options and Lead Manager Options to occur on the same day), and trading of the New Shares will commence on 15 February 2023.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

¹ The issue price of \$24.00 represents a 0.2% discount to the closing price of Anteris' shares on 6 February 2023 of \$24.04.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Investor contact

Deanne Curry

GRACosway

E: investors@anteristech.com

M: +61 414 388 997

Media contact

Nick Howe

GRACosway

nhowe@gracosway.com.au

M: +61 407 183 221

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>